about
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyIntravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles.Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).Lipids and HCV.Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users.IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.FibroGENE: A gene-based model for staging liver fibrosis.Hepatitis C virus and atherosclerosis: A legacy after virologic cure?Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency.Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial.Iron deficiency anaemia in chronic inflammatory rheumatic diseases: low mean cell haemoglobin is a better marker than low mean cell volume.Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection.Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin.Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey.TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanismsAccuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseAcute myeloid leukaemia: an unusual cause of biliary stricturesLipid interactions influence hepatitis C virus susceptibility and resistance to infection
P50
Q28477057-C460705F-B744-4BA0-84BD-AC752A1AD953Q33648622-9155E07D-B545-4331-BAE2-1B2949172BA4Q35197060-229C77EB-3E2C-4B48-B0F2-A90A6C4DAE9CQ37264708-2A246F39-EF33-4FD1-B939-BD01C721729AQ38041738-0BEBFB71-CF46-4C11-A56B-1635AFCA50EEQ38056643-8F445664-9FE1-4903-AB7B-2F4E9DBED610Q39285745-5A4DA6AF-202E-420A-BA1D-620B007F3C94Q40258100-5B6DD613-025C-4FBB-84DA-363507A60078Q40291661-0D05B598-1049-489F-8A5A-24C56F73A64EQ40453978-D02DAEE2-5195-414D-9381-66DEBE6F7179Q40659995-CC876C8B-CCFB-4E43-895A-446D00109C9EQ40813737-46DF4BBB-B962-4A2C-B9D2-E1B97FC5F901Q41625284-219B8970-5D76-4F9C-A43D-19C67C52E748Q42222091-8C179690-0C60-4BB4-A3EA-588AE07D81D9Q42232478-53686C70-7109-4B93-A673-252EE2DAC9E9Q42263066-378FB80E-D969-4CBE-8E89-88DDDA6289E9Q42781029-76335000-FF23-49B5-BB79-52C2D7B9A9B5Q43000587-8C428E52-8376-476F-97BC-5DC784014E90Q43623654-085DDB48-2D25-42F0-BC95-00100FA36A9BQ45385107-7528988F-207B-4AE4-BBE3-5CEDA781AC7DQ47234787-B2E33E0A-5C85-46A3-A3E9-6B97F030A721Q49380683-E3949B89-E22E-4BAF-BC29-27877AFC4B6CQ61799569-E13C3586-2517-4289-B04B-133B37E2CE70Q91251078-11B22FC9-9F69-4674-93B8-0B71C6FB93E4Q92369432-76AD461C-8D16-4E72-B65C-39D0BB937AB9Q93140180-56FD2A84-6182-478C-920D-7D4992B41A4E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Sheridan
@ast
David Sheridan
@en
David Sheridan
@es
David Sheridan
@nl
David Sheridan
@sl
type
label
David Sheridan
@ast
David Sheridan
@en
David Sheridan
@es
David Sheridan
@nl
David Sheridan
@sl
prefLabel
David Sheridan
@ast
David Sheridan
@en
David Sheridan
@es
David Sheridan
@nl
David Sheridan
@sl
P106
P1153
35184091100
P21
P31
P496
0000-0001-5100-814X